Triventures

Triventures is a venture capital firm founded in 2010 and headquartered in Herzliya, Israel, with an office in California. It invests across incubation, seed, startup, and early- and mid-stage rounds, focusing on health technology such as medical devices, digital health, health data marketplaces, and genomics, as well as related areas like insurtech, fintech for healthcare, e-commerce, and cybersecurity for healthcare. The firm maintains a global reach across Israel, the United States and Europe, backing startups led by experienced entrepreneurs and pursuing cross-industry breakthroughs at the intersection of health and other technologies. Its team combines healthcare expertise with venture and business development know-how to identify and support ambitious founders.

Dani Goldsher

CFO and Partner

Lihi Lubranski

Principal

58 past transactions

Cala Health

Series C in 2024
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

TailorMed

Series B in 2024
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Grin

Venture Round in 2024
Grin is a digital orthodontic platform that connects patients with local orthodontists through its mobile app. It offers remote monitoring and high-quality self-scans for various teeth straightening needs, providing convenient and accessible care.

Monogoto

Series A in 2024
Monogoto provides a cloud-based cellular network and API-driven Infrastructure-as-a-Service that enables enterprises to integrate cellular connectivity with their existing IT infrastructure. The platform supports IoT, private LTE, and 5G use cases with edge-to-cloud security, comprehensive network event auditing, anomaly detection, and automated alerts. It offers an enterprise-friendly, zero CAPEX, as-a-Service model and global reach, with public connectivity in many countries and options for roaming across private and public networks. The solution supports on-premise local breakout for private networks and private wireless broadband, helping organizations achieve secure, scalable cellular connectivity with centralized management and roaming capabilities worldwide.

Brightside Health

Series C in 2024
Brightside Health is a telemedicine platform focused on mental health treatment for anxiety and depression. It delivers evidence-based care through video visits, messaging, ongoing support, and medication delivery, backed by a network of providers who conduct depression evaluation, treatment, and monitoring. The platform combines precision psychiatry with clinically proven therapy and continuous care monitoring to help patients achieve and maintain improvement. It supports communication, scheduling, and access to information about health and wellness related to depression, and tracks progress throughout treatment. Founded in 2017 and based in San Francisco.

BioProtect

Venture Round in 2023
BioProtect specializes in developing and commercializing biodegradable balloon spacers to protect normal tissue during cancer radiation therapy. Its flagship product, ProSpace, has demonstrated superior efficacy and safety in protecting the rectum during prostate cancer radiotherapy. BioProtect's technology platform caters to a wide range of applications for unmet clinical needs.

FeelBetter

Venture Round in 2023
FeelBetter is a healthcare optimization platform founded in 2018 and based in Tel Aviv, Israel. The company focuses on value-based models to identify at-risk patients and appropriate interventions. Its platform enhances financial and clinical outcomes by analyzing individual patients' health journeys and diagnosing necessary interventions before deterioration occurs. By delivering personalized data and actionable insights, FeelBetter enables healthcare organizations to improve patient outcomes and overall business results.

Flow Specialty (Previously Capitola)

Series A in 2023
Flow is the Next-Gen Specialty Brokerage for commercial insurance. We blend human expertise with cutting-edge technology to deliver access to top markets.

FEMSelect

Series B in 2022
FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.

Future Family

Series B in 2022
Future Family, Inc. is a subscription-based fertility company founded in 2016 and headquartered in San Francisco, California. It provides comprehensive healthcare solutions for individuals and couples navigating fertility challenges, offering plans that cover all associated costs. The company's services include personalized fertility planning, clinic matching, and a dedicated nurse concierge, ensuring 24/7 access to a care team. Future Family specializes in on-demand medical support for procedures such as in vitro fertilization (IVF) and egg freezing, and it features a digital health platform for managing fertility care. By combining financial assistance with expert guidance, Future Family aims to deliver a stress-free fertility experience for its clients.

PayGround

Convertible Note in 2022
PayGround, Inc. is a technology company that specializes in developing billing and payment software solutions for the healthcare industry. Founded in 2018 and headquartered in Chandler, Arizona, PayGround provides a cloud-based platform that allows healthcare providers to efficiently manage patient accounts, create and send invoices, and track billing analytics. The platform simplifies the payment process by enabling providers to upload accounts receivable and initiate digital payment requests through various channels, including email, text, and U.S. Mail. Patients benefit from the service by being able to view and pay their bills quickly, facilitating a smoother billing experience. By streamlining financial interactions between healthcare providers and patients, PayGround aims to reduce costs and eliminate the complexities associated with managing multiple billing accounts.

Brightside Health

Series B in 2022
Brightside Health is a telemedicine platform focused on mental health treatment for anxiety and depression. It delivers evidence-based care through video visits, messaging, ongoing support, and medication delivery, backed by a network of providers who conduct depression evaluation, treatment, and monitoring. The platform combines precision psychiatry with clinically proven therapy and continuous care monitoring to help patients achieve and maintain improvement. It supports communication, scheduling, and access to information about health and wellness related to depression, and tracks progress throughout treatment. Founded in 2017 and based in San Francisco.

Day Zero Diagnostics

Venture Round in 2022
Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

V-Wave

Series C in 2021
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Monogoto

Seed Round in 2021
Monogoto provides a cloud-based cellular network and API-driven Infrastructure-as-a-Service that enables enterprises to integrate cellular connectivity with their existing IT infrastructure. The platform supports IoT, private LTE, and 5G use cases with edge-to-cloud security, comprehensive network event auditing, anomaly detection, and automated alerts. It offers an enterprise-friendly, zero CAPEX, as-a-Service model and global reach, with public connectivity in many countries and options for roaming across private and public networks. The solution supports on-premise local breakout for private networks and private wireless broadband, helping organizations achieve secure, scalable cellular connectivity with centralized management and roaming capabilities worldwide.

TailorMed

Venture Round in 2021
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Brightside Health

Series A in 2021
Brightside Health is a telemedicine platform focused on mental health treatment for anxiety and depression. It delivers evidence-based care through video visits, messaging, ongoing support, and medication delivery, backed by a network of providers who conduct depression evaluation, treatment, and monitoring. The platform combines precision psychiatry with clinically proven therapy and continuous care monitoring to help patients achieve and maintain improvement. It supports communication, scheduling, and access to information about health and wellness related to depression, and tracks progress throughout treatment. Founded in 2017 and based in San Francisco.

Grin

Seed Round in 2021
Grin is a digital orthodontic platform that connects patients with local orthodontists through its mobile app. It offers remote monitoring and high-quality self-scans for various teeth straightening needs, providing convenient and accessible care.

EyeYon Medical

Series C in 2021
EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

BurnAlong

Venture Round in 2021
BurnAlong, Inc. is a technology company that has developed an online fitness and wellness video application designed to enhance personal well-being through social motivation and tailored fitness experiences. Founded in 2016 and headquartered in Pikesville, Maryland, BurnAlong allows users to participate in health and fitness classes via video feed, connecting them with friends, fitness instructors, and a broader community. The platform employs machine learning to provide personalized recommendations, catering to a diverse audience that includes corporate employers, municipalities, insurers, individuals, and senior citizens. By facilitating engaging wellness classes, BurnAlong aims to help individuals achieve their health and wellness goals while promoting a positive culture within organizations.

PayGround

Seed Round in 2021
PayGround, Inc. is a technology company that specializes in developing billing and payment software solutions for the healthcare industry. Founded in 2018 and headquartered in Chandler, Arizona, PayGround provides a cloud-based platform that allows healthcare providers to efficiently manage patient accounts, create and send invoices, and track billing analytics. The platform simplifies the payment process by enabling providers to upload accounts receivable and initiate digital payment requests through various channels, including email, text, and U.S. Mail. Patients benefit from the service by being able to view and pay their bills quickly, facilitating a smoother billing experience. By streamlining financial interactions between healthcare providers and patients, PayGround aims to reduce costs and eliminate the complexities associated with managing multiple billing accounts.

Medisafe

Series C in 2021
Medisafe is a digital patient engagement platform that focuses on enhancing medication management and improving patient adherence. By utilizing billions of data points, the platform personalizes patient interactions and addresses the significant challenges associated with medication non-adherence. Medisafe’s solutions have been shown to increase adherence rates by up to 20%, supported by extensive studies involving tens of thousands of patients. The platform is designed to engage patients throughout their medication journey while providing valuable insights into their behavior patterns, which are crucial for enhancing the overall patient experience. With nearly 5 million registered users across various devices, Medisafe has recorded over 2 billion medication doses and has received high ratings from users, averaging 4.7 out of 5 stars. The company has garnered several accolades, including recognition as a Gartner Cool Vendor and being named one of the Most Innovative in Healthcare by Fast Company. Medisafe’s mission is to empower patients and facilitate better communication between them and their healthcare providers, ultimately improving health outcomes.

Genoox

Series B in 2021
Genoox, Ltd. is a company that develops a cloud-based platform dedicated to managing and analyzing genomic data. Founded in 2014 by Amir Trabelsi and Moshe Einhorn, the company is headquartered in Palo Alto, California. Genoox's platform harnesses artificial intelligence and machine-learning algorithms to translate complex genetic information into actionable clinical insights, thereby facilitating genetic diagnostics and personalized treatment options for patients. The platform connects clinicians, genetic counselors, and healthcare organizations, creating a collaborative network that enhances the sharing of genetic insights. With over 1,700 health organizations, hospitals, and medical facilities utilizing its services across 44 markets globally, Genoox aims to establish the largest real-world evidence network of genomic and clinical data, ultimately improving patient outcomes through more effective and efficient data handling.

V-Wave

Series C in 2020
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

BioProtect

Series D in 2020
BioProtect specializes in developing and commercializing biodegradable balloon spacers to protect normal tissue during cancer radiation therapy. Its flagship product, ProSpace, has demonstrated superior efficacy and safety in protecting the rectum during prostate cancer radiotherapy. BioProtect's technology platform caters to a wide range of applications for unmet clinical needs.

Tunefork

Seed Round in 2020
TuneFork is a company specializing in audio personalization technology software aimed at delivering an optimal hearing experience across various devices. The software guides users through a clinically accurate self-test to create a personalized Audio Profile, which characterizes individual hearing capabilities. This profile is then used to tailor precise audio filters, ensuring the best possible match between the user's sound system and their unique hearing characteristics. TuneFork can be integrated into any operating or network system to optimize all types of audio content, including phone calls, music, video, voice messages, and alerts. The technology is particularly beneficial for smartphones, which are widely used for communication, entertainment, and social networking. By enhancing the audio experience, TuneFork not only improves sound quality but also helps mitigate potential hearing damage from unbalanced audio.

Lynx.MD

Seed Round in 2019
Latica, formerly known as Lynx.MD, is a healthcare data company established in 2019 that focuses on transforming medical research and patient care through a secure data ecosystem. The company offers a platform that enables life sciences organizations, healthcare providers, and researchers to access and collaborate on clinical and operational data. By employing advanced technologies such as artificial intelligence and data analytics, Latica aims to unlock the potential of previously siloed healthcare data, facilitating meaningful advancements in medical research while prioritizing patient privacy and security. The platform fosters collaboration among various stakeholders in the healthcare sector, providing actionable insights that enhance outcomes for patients and improve the efficiency of healthcare delivery.

TailorMed

Series A in 2019
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Cala Health

Series C in 2019
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

TailorMed

Series A in 2019
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Day Zero Diagnostics

Series A in 2019
Day Zero Diagnostics Inc. is an innovative company focused on transforming infectious disease diagnostics through advanced sequencing technologies. Based in Boston, Massachusetts, the company has developed a rapid diagnostic system that identifies bacterial species and their antibiotic resistance profiles directly from clinical samples. Key technologies include Blood2Bac, which enriches bacterial DNA, and BacDetect, allowing for swift detection of bacterial DNA. Additionally, the company employs machine learning algorithms for genomic antibiotic susceptibility testing and maintains a comprehensive microbial database that integrates genomic sequencing data with resistance profiles. By enabling rapid and accurate diagnoses, Day Zero Diagnostics aims to address critical needs in managing bloodstream infections and sepsis, reducing the time for diagnosis from days to hours and improving patient outcomes through targeted treatments.

Lynx.MD

Pre Seed Round in 2019
Latica, formerly known as Lynx.MD, is a healthcare data company established in 2019 that focuses on transforming medical research and patient care through a secure data ecosystem. The company offers a platform that enables life sciences organizations, healthcare providers, and researchers to access and collaborate on clinical and operational data. By employing advanced technologies such as artificial intelligence and data analytics, Latica aims to unlock the potential of previously siloed healthcare data, facilitating meaningful advancements in medical research while prioritizing patient privacy and security. The platform fosters collaboration among various stakeholders in the healthcare sector, providing actionable insights that enhance outcomes for patients and improve the efficiency of healthcare delivery.

Genoox

Series B in 2018
Genoox, Ltd. is a company that develops a cloud-based platform dedicated to managing and analyzing genomic data. Founded in 2014 by Amir Trabelsi and Moshe Einhorn, the company is headquartered in Palo Alto, California. Genoox's platform harnesses artificial intelligence and machine-learning algorithms to translate complex genetic information into actionable clinical insights, thereby facilitating genetic diagnostics and personalized treatment options for patients. The platform connects clinicians, genetic counselors, and healthcare organizations, creating a collaborative network that enhances the sharing of genetic insights. With over 1,700 health organizations, hospitals, and medical facilities utilizing its services across 44 markets globally, Genoox aims to establish the largest real-world evidence network of genomic and clinical data, ultimately improving patient outcomes through more effective and efficient data handling.

Webotex

Venture Round in 2018
Full-service website design and development for local service-based companies.

V-Wave

Series C in 2018
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Vi Labs

Series A in 2018
Vi Labs is a leading provider of enterprise AI platforms in the healthcare sector. It helps healthcare enterprises optimize member health outcomes and financial returns by leveraging data and AI.

CathWorks

Series B in 2017
CathWorks is a medical technology company that applies computational science platforms to enhance percutaneous coronary intervention (PCI) therapy decisions. It offers CathWorks FFRangio, a non-invasive device delivering objective multi-vessel physiologic measurements to optimize and confirm intra-procedural PCI therapies.

Colospan

Venture Round in 2017
Colospan is a medical device company specializing in colorectal surgery. Founded in 2010, it develops innovative products to prevent anastomotic leaks and diverting colonic stomas during intestinal surgeries.

Colospan

Series B in 2017
Colospan is a medical device company specializing in colorectal surgery. Founded in 2010, it develops innovative products to prevent anastomotic leaks and diverting colonic stomas during intestinal surgeries.

ZingBox

Series B in 2017
ZingBox, established in 2014 and headquartered in Mountain View, California, specializes in enterprise Internet of Things (IoT) security. It offers a real-time IoT security solution that discovers and protects connected equipment, safeguarding against cyber and insider threats. Primarily serving the healthcare and manufacturing industries, ZingBox's platform detects anomalous behavior, maps networks, and generates risk profiles. It operates as a subsidiary of Palo Alto Networks, Inc.

EyeYon Medical

Venture Round in 2017
EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

Medisafe

Series B in 2017
Medisafe is a digital patient engagement platform that focuses on enhancing medication management and improving patient adherence. By utilizing billions of data points, the platform personalizes patient interactions and addresses the significant challenges associated with medication non-adherence. Medisafe’s solutions have been shown to increase adherence rates by up to 20%, supported by extensive studies involving tens of thousands of patients. The platform is designed to engage patients throughout their medication journey while providing valuable insights into their behavior patterns, which are crucial for enhancing the overall patient experience. With nearly 5 million registered users across various devices, Medisafe has recorded over 2 billion medication doses and has received high ratings from users, averaging 4.7 out of 5 stars. The company has garnered several accolades, including recognition as a Gartner Cool Vendor and being named one of the Most Innovative in Healthcare by Fast Company. Medisafe’s mission is to empower patients and facilitate better communication between them and their healthcare providers, ultimately improving health outcomes.

OrthoSpace

Venture Round in 2016
OrthoSpace Ltd. is an Israeli company that specializes in the development and commercialization of biodegradable balloon systems designed for the orthopedic market, specifically targeting rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating effective solutions that alleviate pain, improve patients' range of motion, and preserve bone and joint structures. Its flagship product, InSpace™, has received CE marking and is marketed in Europe. This innovative balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head, which facilitates smooth movement and reduces friction between the bones. OrthoSpace operates under the umbrella of Stryker Corporation, enhancing its capabilities in delivering advanced orthopedic solutions.

Vi Labs

Seed Round in 2016
Vi Labs is a leading provider of enterprise AI platforms in the healthcare sector. It helps healthcare enterprises optimize member health outcomes and financial returns by leveraging data and AI.

V-Wave

Series B in 2016
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

6over6

Venture Round in 2015
6over6 is a digital healthcare company that has developed a platform allowing users to conduct their own eye vision tests using their smartphones. By integrating essential optometric tools into a mobile application, the company enables users to obtain accurate measurements of refractive errors, which are necessary for eyeglasses and contact lens prescriptions. Their product, GlassesOn, is registered as a Class 1 Exempt Medical Device with the FDA, emphasizing the company's commitment to safety and regulatory compliance. While GlassesOn facilitates effective vision assessment, it does not offer medical advice and is not a substitute for a comprehensive eye health examination. Through this innovative approach, 6over6 aims to enhance accessibility to vision care for a broader audience.

MST Medical Surgery Technologies

Series C in 2015
MST Medical Surgery Technologies Ltd., founded in 2005 and headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida, specializes in developing advanced image analysis software for the healthcare industry. The company is a leader in surgical analytics, focusing on medical robotics and computer-assisted surgery. Its flagship product, AutoLap, is an innovative robotic image-guided laparoscope positioning system that enhances the precision and control of surgical procedures by providing real-time guidance based on the surgeon's movements. Additionally, MST offers Surgical Training Analytics (STA), a tool designed to capture images from actual surgical procedures, aiding in the training of new surgeons. By leveraging advanced visualization, artificial intelligence, and machine learning, MST aims to transform the operating room with automated, data-driven solutions that improve outcomes for both surgeons and patients.

OrthoSpace

Venture Round in 2015
OrthoSpace Ltd. is an Israeli company that specializes in the development and commercialization of biodegradable balloon systems designed for the orthopedic market, specifically targeting rotator cuff syndrome. Founded in 2009 and based in Caesarea, the company focuses on creating effective solutions that alleviate pain, improve patients' range of motion, and preserve bone and joint structures. Its flagship product, InSpace™, has received CE marking and is marketed in Europe. This innovative balloon system mimics the function of the original bursa, acting as a spacer between the acromion and the humeral head, which facilitates smooth movement and reduces friction between the bones. OrthoSpace operates under the umbrella of Stryker Corporation, enhancing its capabilities in delivering advanced orthopedic solutions.

AngioSlide

Series E in 2015
Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

EyeYon Medical

Venture Round in 2015
EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

Medisafe

Series A in 2015
Medisafe is a digital patient engagement platform that focuses on enhancing medication management and improving patient adherence. By utilizing billions of data points, the platform personalizes patient interactions and addresses the significant challenges associated with medication non-adherence. Medisafe’s solutions have been shown to increase adherence rates by up to 20%, supported by extensive studies involving tens of thousands of patients. The platform is designed to engage patients throughout their medication journey while providing valuable insights into their behavior patterns, which are crucial for enhancing the overall patient experience. With nearly 5 million registered users across various devices, Medisafe has recorded over 2 billion medication doses and has received high ratings from users, averaging 4.7 out of 5 stars. The company has garnered several accolades, including recognition as a Gartner Cool Vendor and being named one of the Most Innovative in Healthcare by Fast Company. Medisafe’s mission is to empower patients and facilitate better communication between them and their healthcare providers, ultimately improving health outcomes.

BioGaming

Series A in 2014
BioGaming is a company focused on enhancing rehabilitation outcomes through innovative technology. It has developed an at-home virtual reality exercise platform that gamifies physiotherapy, making the rehabilitation process more engaging for patients. The platform integrates motion analysis systems with clinically developed exercise routines, immersing patients in a virtual environment where therapy becomes more enjoyable. This approach enables physical therapists to prescribe exercise programs that are transformed into interactive games while monitoring patient performance remotely. Using advanced machine learning algorithms, BioGaming generates detailed quantitative and qualitative reports that help both patients and therapists understand progress, ensuring a comprehensive and effective rehabilitation experience.

Cardiva Medical

Venture Round in 2014
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.

Apica Cardiovascular

Venture Round in 2014
Apica Cardiovascular is a pre-revenue medical device company specializing in a technology for accessing and closing the heart's apex and peripheral vascular system. This technology standardizes access and closure for large bore therapeutic devices without blood loss, enabling minimally invasive surgical or percutaneous procedures on the beating heart. It has applications in Transcatheter Heart Valves (TAVI), Abdominal Aortic Aneurysm (AAA) repair, and Left Ventricular Assist Device (LVAD) implantation. After successful animal and cadaver model testing, the technology is now advancing towards initial clinical trials.

Medisafe

Seed Round in 2013
Medisafe is a digital patient engagement platform that focuses on enhancing medication management and improving patient adherence. By utilizing billions of data points, the platform personalizes patient interactions and addresses the significant challenges associated with medication non-adherence. Medisafe’s solutions have been shown to increase adherence rates by up to 20%, supported by extensive studies involving tens of thousands of patients. The platform is designed to engage patients throughout their medication journey while providing valuable insights into their behavior patterns, which are crucial for enhancing the overall patient experience. With nearly 5 million registered users across various devices, Medisafe has recorded over 2 billion medication doses and has received high ratings from users, averaging 4.7 out of 5 stars. The company has garnered several accolades, including recognition as a Gartner Cool Vendor and being named one of the Most Innovative in Healthcare by Fast Company. Medisafe’s mission is to empower patients and facilitate better communication between them and their healthcare providers, ultimately improving health outcomes.

AngioSlide

Series D in 2013
Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Cardiva Medical

Venture Round in 2012
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.

FEMSelect

FEMSelect Inc., founded in 2012, is a medical device company focused on improving women's health through innovative surgical solutions. Based in Newark, Delaware, FEMSelect develops minimally-invasive and mesh-free systems for pelvic floor ligament fixation. Their flagship product, EnPlace, is designed to treat pelvic organ prolapse (POP) by precisely guiding, inserting, and deploying an anchor unit through the vaginal wall to stabilize the pelvic floor ligament. The procedure typically takes around 30 minutes and does not require overnight hospital stays or result in significant scarring.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.